Published in Proc Natl Acad Sci U S A on December 09, 1997
Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer (2008) 4.27
Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol (2000) 3.18
Integrins: roles in cancer development and as treatment targets. Br J Cancer (2004) 2.76
Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci U S A (2000) 2.46
Proteoglycans in cancer biology, tumour microenvironment and angiogenesis. J Cell Mol Med (2011) 2.21
Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A (2001) 2.19
Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol (1999) 1.99
Endothelial lumen signaling complexes control 3D matrix-specific tubulogenesis through interdependent Cdc42- and MT1-MMP-mediated events. Blood (2010) 1.98
Proteoglycan form and function: A comprehensive nomenclature of proteoglycans. Matrix Biol (2015) 1.91
Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J (2005) 1.89
The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am J Pathol (2002) 1.75
A cell-based model exhibiting branching and anastomosis during tumor-induced angiogenesis. Biophys J (2007) 1.74
RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. Am J Pathol (2000) 1.68
Rho activity critically and selectively regulates endothelial cell organization during angiogenesis. Proc Natl Acad Sci U S A (2004) 1.67
Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. J Clin Invest (2005) 1.66
Stable interaction between alpha5beta1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1. J Cell Biol (2005) 1.61
Why integrin as a primary target for imaging and therapy. Theranostics (2011) 1.61
Regulation of inflammation by collagen-binding integrins alpha1beta1 and alpha2beta1 in models of hypersensitivity and arthritis. J Clin Invest (2000) 1.60
Radiolabeled arginine-glycine-aspartic acid peptides to image angiogenesis in swine model of hibernating myocardium. JACC Cardiovasc Imaging (2008) 1.57
Active Rac1 improves pathologic VEGF neovessel architecture and reduces vascular leak: mechanistic similarities with angiopoietin-1. Blood (2010) 1.56
Involvement of insulin receptor substrate 2 in mammary tumor metastasis. Mol Cell Biol (2004) 1.55
Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol (2003) 1.55
Activated Notch4 inhibits angiogenesis: role of beta 1-integrin activation. Mol Cell Biol (2002) 1.52
Mathematical modeling of tumor-induced angiogenesis. J Math Biol (2004) 1.51
Cell-autonomous requirement for beta1 integrin in endothelial cell adhesion, migration and survival during angiogenesis in mice. Development (2008) 1.41
Angiogenesis. Cold Spring Harb Perspect Biol (2011) 1.37
Molecular basis for endothelial lumen formation and tubulogenesis during vasculogenesis and angiogenic sprouting. Int Rev Cell Mol Biol (2011) 1.36
Blocking ligand occupancy of the alphaVbeta3 integrin inhibits insulin-like growth factor I signaling in vascular smooth muscle cells. Proc Natl Acad Sci U S A (1998) 1.32
Integrin alpha 11 regulates IGF2 expression in fibroblasts to enhance tumorigenicity of human non-small-cell lung cancer cells. Proc Natl Acad Sci U S A (2007) 1.29
Semaphorin-4A, an activator for T-cell-mediated immunity, suppresses angiogenesis via Plexin-D1. EMBO J (2007) 1.28
The extracellular matrix and blood vessel formation: not just a scaffold. J Cell Mol Med (2007) 1.25
Molecular mechanisms controlling vascular lumen formation in three-dimensional extracellular matrices. Cells Tissues Organs (2011) 1.19
Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis. Mol Cell Biol (2006) 1.19
Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. Adv Drug Deliv Rev (2012) 1.18
Roles of integrins in tumor angiogenesis and lymphangiogenesis. Lymphat Res Biol (2008) 1.16
Vascular endothelial growth factor mediates corneal nerve repair. Invest Ophthalmol Vis Sci (2008) 1.13
Moderation of calpain activity promotes neovascular integration and lumen formation during VEGF-induced pathological angiogenesis. PLoS One (2010) 1.11
Integrins and bone metastasis: integrating tumor cell and stromal cell interactions. Bone (2010) 1.09
Alpha 5 beta 1 integrin activates an NF-kappa B-dependent program of gene expression important for angiogenesis and inflammation. Mol Cell Biol (2002) 1.08
Breast cancer-induced angiogenesis: multiple mechanisms and the role of the microenvironment. Breast Cancer Res (2003) 1.07
A key role for the integrin alpha2beta1 in experimental and developmental angiogenesis. Am J Pathol (2009) 1.07
Integrins as "functional hubs" in the regulation of pathological angiogenesis. Semin Cancer Biol (2009) 1.05
Tumor angiogenesis: insights and innovations. J Oncol (2010) 1.04
Endorepellin, the angiostatic module of perlecan, interacts with both the α2β1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism. J Biol Chem (2011) 1.04
Oxidative stress-responsive transcription factor ATF3 potentially mediates diabetic angiopathy. Mol Cell Biol (2006) 1.03
The role of alphav integrins during angiogenesis. Mol Med (1998) 1.03
alpha2beta1 integrin expression in the tumor microenvironment enhances tumor angiogenesis in a tumor cell-specific manner. Blood (2007) 1.03
Analysis of VEGF-responsive genes involved in the activation of endothelial cells. Mol Cancer (2003) 1.02
Characterization of the anti-angiogenic properties of arresten, an alpha1beta1 integrin-dependent collagen-derived tumor suppressor. Exp Cell Res (2008) 1.02
Role of the cytoskeleton in formation and maintenance of angiogenic sprouts. J Vasc Res (2011) 1.01
Enhanced skin wound healing by a sustained release of growth factors contained in platelet-rich plasma. Exp Mol Med (2011) 1.00
Role of the integrin alphaVbeta3 in mediating increased smooth muscle cell responsiveness to IGF-I in response to hyperglycemic stress. Growth Horm IGF Res (2007) 0.99
Molecular mediators of angiogenesis. J Burn Care Res (2010) 0.98
Integrins and their ligands in rheumatoid arthritis. Arthritis Res Ther (2011) 0.97
Cdc42-mediated inhibition of GSK-3β improves angio-architecture and lumen formation during VEGF-driven pathological angiogenesis. Microvasc Res (2010) 0.97
Functional analysis of the cytoplasmic domain of the integrin {alpha}1 subunit in endothelial cells. Blood (2008) 0.97
Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis. Blood (2007) 0.96
Acute and impaired wound healing: pathophysiology and current methods for drug delivery, part 2: role of growth factors in normal and pathological wound healing: therapeutic potential and methods of delivery. Adv Skin Wound Care (2012) 0.95
Halofuginone inhibits angiogenesis and growth in implanted metastatic rat brain tumor model--an MRI study. Neoplasia (2004) 0.95
Loss of integrin alpha1beta1 ameliorates Kras-induced lung cancer. Cancer Res (2008) 0.94
OmpA-mediated rickettsial adherence to and invasion of human endothelial cells is dependent upon interaction with α2β1 integrin. Cell Microbiol (2012) 0.93
Potential therapeutic strategies for lymphatic metastasis. Microvasc Res (2007) 0.92
Vascular endothelial growth factor promotes anatomical and functional recovery of injured peripheral nerves in the avascular cornea. FASEB J (2013) 0.92
Hydrogel macroporosity and the prolongation of transgene expression and the enhancement of angiogenesis. Biomaterials (2012) 0.89
Angiogenesis in cancer: Anti-VEGF escape mechanisms. Transl Lung Cancer Res (2012) 0.87
Proteomic profiling of endorepellin angiostatic activity on human endothelial cells. Proteome Sci (2008) 0.87
An angiogenic role for the α5β1 integrin in promoting endothelial cell proliferation during cerebral hypoxia. Exp Neurol (2012) 0.87
Endorepellin evokes autophagy in endothelial cells. J Biol Chem (2014) 0.86
Anti-angiogenic effects of non-peptide integrin alphavbeta3 specific antagonist on laser-induced choroidal neovascularization in mice. Graefes Arch Clin Exp Ophthalmol (2008) 0.85
VEGF expression by epithelial and stromal cell compartments: resolving a controversy. Am J Pathol (2000) 0.85
Therapeutic targeting of redox signaling in myofibroblast differentiation and age-related fibrotic disease. Oxid Med Cell Longev (2012) 0.85
Redox signaling as a therapeutic target to inhibit myofibroblast activation in degenerative fibrotic disease. Biomed Res Int (2014) 0.84
ECM-based materials in cardiovascular applications: Inherent healing potential and augmentation of native regenerative processes. Int J Mol Sci (2009) 0.84
Role of vascular endothelial growth factor (VEGF) and VEGF-R genotyping in guiding the metastatic process in pT4a resected gastric cancer patients. PLoS One (2012) 0.84
Expression of integrins in human proliferative diabetic retinopathy membranes. Can J Ophthalmol (2008) 0.84
Genomic and proteomic analysis of the impact of mitotic quiescence on the engraftment of human CD34+ cells. PLoS One (2011) 0.83
Lessons from the alpha2 integrin knockout mouse. Am J Pathol (2002) 0.83
Disintegrins from snake venoms and their applications in cancer research and therapy. Curr Protein Pept Sci (2015) 0.83
Stable engineered vascular networks from human induced pluripotent stem cell-derived endothelial cells cultured in synthetic hydrogels. Acta Biomater (2016) 0.83
Angiostatic activity of obtustatin as alpha1beta1 integrin inhibitor in experimental melanoma growth. Int J Cancer (2008) 0.82
Extracellular matrix modulates angiogenesis in physiological and pathological conditions. Biomed Res Int (2014) 0.80
Bioactive polymer scaffold for fabrication of vascularized engineering tissue. J Artif Organs (2012) 0.80
Fibrin and collagen differentially but synergistically regulate sprout angiogenesis of human dermal microvascular endothelial cells in 3-dimensional matrix. Int J Cell Biol (2013) 0.80
Integrin-mediated cell-matrix interaction in physiological and pathological blood vessel formation. J Oncol (2011) 0.79
Developmental and injury-induced expression of alpha1beta1 and alpha6beta1 integrins in the rat spinal cord. Brain Res (2006) 0.78
Vixapatin (VP12), a c-type lectin-protein from Vipera xantina palestinae venom: characterization as a novel anti-angiogenic compound. Toxins (Basel) (2012) 0.78
Endothelial cell response to chemical, biological, and physical cues in bioactive hydrogels. Tissue Eng Part A (2014) 0.78
Identification of inhibitors of α2β1 integrin, members of C-lectin type proteins, in Echis sochureki venom. Toxicol Appl Pharmacol (2013) 0.77
Molecular mechanism of local drug delivery with Paclitaxel-eluting membranes in biliary and pancreatic cancer: new application for an old drug. Gastroenterol Res Pract (2015) 0.77
Integrin alpha1beta1 is involved in the differentiation into myofibroblasts in adult reactive tissues in vivo. J Cell Mol Med (2008) 0.77
Expression of integrins on human choroidal neovascular membranes. J Ocul Biol Dis Infor (2009) 0.77
The role of perlecan and endorepellin in the control of tumor angiogenesis and endothelial cell autophagy. Connect Tissue Res (2015) 0.77
Induction of integrin α2 in a highly bone metastatic human prostate cancer cell line: roles of RANKL and AR under three-dimensional suspension culture. Mol Cancer (2014) 0.77
Breast cancer cells alter the dynamics of stromal fibronectin-collagen interactions. Matrix Biol (2016) 0.76
Integrin-specific hydrogels functionalized with VEGF for vascularization and bone regeneration of critical-size bone defects. J Biomed Mater Res A (2016) 0.76
Sulfonamide inhibitors of α2β1 integrin reveal the essential role of collagen receptors in in vivo models of inflammation. Pharmacol Res Perspect (2015) 0.75
Aggretin Venom Polypeptide as a Novel Anti-angiogenesis Agent by Targeting Integrin alpha2beta1. Sci Rep (2017) 0.75
Integrins: versatility, modulation, and signaling in cell adhesion. Cell (1992) 34.06
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature (1996) 18.47
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70
Angiogenesis. J Biol Chem (1992) 11.29
Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol (1995) 10.61
Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 9.51
Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med (1995) 9.02
Integrins: emerging paradigms of signal transduction. Annu Rev Cell Dev Biol (1995) 8.88
High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell (1993) 7.14
Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A (1995) 5.92
Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A (1995) 5.66
Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med (1992) 4.39
A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest (1992) 4.21
Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest (1995) 3.69
Antibodies to the conserved cytoplasmic domain of the integrin beta 1 subunit react with proteins in vertebrates, invertebrates, and fungi. J Cell Biol (1988) 3.35
Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest (1994) 3.11
Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med (1994) 3.09
Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo. Cancer Res (1996) 2.58
Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med (1994) 2.54
An alpha 2 beta 1 integrin-dependent pinocytic mechanism involving intracellular vacuole formation and coalescence regulates capillary lumen and tube formation in three-dimensional collagen matrix. Exp Cell Res (1996) 2.53
Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol (1996) 2.42
Alteration of collagen-dependent adhesion, motility, and morphogenesis by the expression of antisense alpha 2 integrin mRNA in mammary cells. J Cell Sci (1995) 2.39
An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization. J Cell Sci (1995) 2.38
Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res (1996) 2.36
Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. Proc Natl Acad Sci U S A (1993) 2.32
The human integrin VLA-2 is a collagen receptor on some cells and a collagen/laminin receptor on others. Proc Natl Acad Sci U S A (1989) 2.31
Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci U S A (1996) 2.31
Targeted mutations in cell adhesion genes: what have we learned from them? Dev Biol (1996) 2.05
Affinity of integrins for damaged extracellular matrix: alpha v beta 3 binds to denatured collagen type I through RGD sites. Biochem Biophys Res Commun (1992) 2.04
Trans-dominant inhibition of integrin function. Mol Biol Cell (1996) 1.92
Deletion of integrin alpha 1 by homologous recombination permits normal murine development but gives rise to a specific deficit in cell adhesion. Dev Biol (1996) 1.84
Between molecules and morphology. Extracellular matrix and creation of vascular form. Am J Pathol (1995) 1.72
Integrin alpha 2 beta 1 (VLA-2) mediates reorganization and contraction of collagen matrices by human cells. Cell (1991) 1.65
Molecular cloning of the rat integrin alpha 1-subunit: a receptor for laminin and collagen. J Cell Biol (1990) 1.54
Widespread histologic distribution of the alpha 2 beta 1 integrin cell-surface collagen receptor. Am J Pathol (1990) 1.48
Overexpression of vascular permeability factor (VPF/VEGF) and its endothelial cell receptors in delayed hypersensitivity skin reactions. J Immunol (1995) 1.43
Dynamic expression of alpha 1 beta 1 and alpha 2 beta 1 integrin receptors by human vascular smooth muscle cells. Alpha 2 beta 1 integrin is required for chemotaxis across type I collagen-coated membranes. Am J Pathol (1994) 1.38
Endothelial cell attachment and spreading on human tenascin is mediated by alpha 2 beta 1 and alpha v beta 3 integrins. J Cell Sci (1993) 1.35
Regulation of in vitro capillary tube formation by anti-integrin antibodies. J Cell Biol (1993) 1.34
Antibodies to beta 1-integrins cause alterations of aortic vasculogenesis, in vivo. Dev Dyn (1992) 1.33
Differential distribution and modulation of expression of alpha 1/beta 1 integrin on human endothelial cells. J Cell Biol (1991) 1.29
Molecular framework for angiogenesis: a complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. Am J Pathol (1996) 1.26
The alpha1beta1 integrin is expressed during neointima formation in rat arteries and mediates collagen matrix reorganization. J Clin Invest (1996) 1.15
The role of vascular endothelial growth factor in blood vessel formation. Trends Cell Biol (1996) 1.15
Expression of native and truncated forms of the human integrin alpha 1 subunit. J Biol Chem (1993) 1.14
Loss of MDCK cell alpha 2 beta 1 integrin expression results in reduced cyst formation, failure of hepatocyte growth factor/scatter factor-induced branching morphogenesis, and increased apoptosis. J Cell Sci (1995) 1.10
The effects of growth factors on the day 13 chorioallantoic membrane (CAM): a study of VEGF165 and PDGF-BB. Anat Embryol (Berl) (1992) 1.07
Confocal microscopic analysis of integrin expression on the microvasculature and its sprouts in the neonatal foreskin. J Invest Dermatol (1994) 1.05
Expression of platelet-endothelial cell adhesion molecule-1 (PECAM-1) during melanoma-induced angiogenesis in vivo. J Cutan Pathol (1993) 1.04
Effects of recombinant tumor necrosis factor-alpha on cultured microvascular endothelial cells derived from human dermis. J Invest Dermatol (1990) 0.90
A functional monoclonal antibody recognizing the human alpha 1-integrin I-domain. Tissue Antigens (1996) 0.86
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 15.43
Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol (1995) 10.61
Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med (2001) 7.78
Vascular endothelial cell adherens junction assembly and morphogenesis induced by sphingosine-1-phosphate. Cell (1999) 5.01
A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res (1986) 4.12
Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol (1998) 3.18
Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med (1994) 3.09
Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma. Am J Pathol (2001) 2.89
Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J Clin Invest (2001) 2.78
Lymphatic endothelium and Kaposi's sarcoma spindle cells detected by antibodies against the vascular endothelial growth factor receptor-3. Cancer Res (1998) 2.60
Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J (2000) 2.44
Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. Am J Pathol (1996) 2.42
Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS (1997) 2.24
Osteopontin expression and distribution in human carcinomas. Am J Pathol (1994) 2.09
Control of hair growth and follicle size by VEGF-mediated angiogenesis. J Clin Invest (2001) 2.04
Regulation of human vascular endothelial growth factor mRNA stability in hypoxia by heterogeneous nuclear ribonucleoprotein L. J Biol Chem (1999) 2.02
Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. Proc Natl Acad Sci U S A (1999) 2.01
Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell (1992) 2.00
Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas. Am J Pathol (1999) 1.99
A simple immunomagnetic protocol for the selective isolation and long-term culture of human dermal microvascular endothelial cells. Exp Cell Res (1998) 1.81
Structure, function, and molecular control of the skin lymphatic system. J Investig Dermatol Symp Proc (2000) 1.81
Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res (1988) 1.71
Interaction of tumor cells and lymphatic vessels in cancer progression. Oncogene (2011) 1.67
Hypoxia stimulates breast carcinoma cell invasion through MT1-MMP and MMP-2 activation. Oncogene (2006) 1.63
Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. J Invest Dermatol (1997) 1.56
Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol (1995) 1.55
Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism. EMBO J (2001) 1.51
Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas. Am J Pathol (2000) 1.44
TNF-alpha impairs insulin signaling and insulin stimulation of glucose uptake in C2C12 muscle cells. Am J Physiol (1999) 1.41
Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am J Pathol (1995) 1.41
Identification of a human VPF/VEGF 3' untranslated region mediating hypoxia-induced mRNA stability. Mol Biol Cell (1998) 1.40
Adhesive properties of osteopontin: regulation by a naturally occurring thrombin-cleavage in close proximity to the GRGDS cell-binding domain. Mol Biol Cell (1994) 1.35
Vascular endothelial growth factor-C (VEGF-C) and its receptors KDR and flt-4 are expressed in AIDS-associated Kaposi's sarcoma. J Invest Dermatol (1999) 1.34
Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin. Biochim Biophys Acta (1989) 1.33
Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res (1990) 1.32
In vivo detection of human vascular endothelial growth factor promoter activity in transgenic mouse skin. Am J Pathol (2000) 1.31
Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme. J Invest Dermatol (1995) 1.30
Murine psoriasis-like disorder induced by naive CD4+ T cells. Nat Med (1997) 1.29
Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Res Treat (2011) 1.23
Control of the adipsin gene in adipocyte differentiation. Identification of distinct nuclear factors binding to single- and double-stranded DNA. J Biol Chem (1990) 1.21
Activation of Sp1-mediated vascular permeability factor/vascular endothelial growth factor transcription requires specific interaction with protein kinase C zeta. J Biol Chem (1998) 1.19
Vascular permeability factor, tumor angiogenesis and stroma generation. Invasion Metastasis (1995) 1.16
A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature (1983) 1.15
Role of AP-1 and HIF-1 transcription factors in TGF-beta activation of VEGF expression. Growth Factors (2001) 1.11
Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochim Biophys Acta (1996) 1.11
Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells. Oncogene (1997) 1.09
Gangliosides influence angiogenesis in an experimental mouse brain tumor. Cancer Res (1999) 1.04
Ultraviolet B irradiation of human skin induces an angiogenic switch that is mediated by upregulation of vascular endothelial growth factor and by downregulation of thrombospondin-1. Br J Dermatol (2005) 1.04
The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways. J Biol Chem (1997) 1.02
Uterine smooth muscle cells express functional receptors (flt-1 and KDR) for vascular permeability factor/vascular endothelial growth factor. Lab Invest (1997) 0.99
Role of protein kinase C isoforms in phorbol ester-induced vascular endothelial growth factor expression in human glioblastoma cells. J Biol Chem (1999) 0.99
Hypoxia-mediated regulation of gene expression in mammalian cells. Int J Exp Pathol (1998) 0.92
The angiogenesis inhibitor vasostatin does not impair wound healing at tumor-inhibiting doses. J Invest Dermatol (2001) 0.91
Effects of rIFN alpha, beta, and gamma on the morphology, proliferation, and cell surface antigen expression of human dermal microvascular endothelial cells in vitro. J Invest Dermatol (1990) 0.91
Dermatan sulfate activates nuclear factor-kappab and induces endothelial and circulating intercellular adhesion molecule-1. J Clin Invest (1999) 0.91
Hypertension induces tissue-specific gene suppression of a fatty acid binding protein in rat aorta. Proc Natl Acad Sci U S A (1988) 0.89
Quantitative lymphatic vessel trait analysis suggests Vcam1 as candidate modifier gene of inflammatory bowel disease. Genes Immun (2010) 0.89
Measurement of rat heart fatty acid binding protein by ELISA. Tissue distribution, developmental changes and subcellular distribution. J Mol Cell Cardiol (1987) 0.89
Growth of human hair follicle keratinocytes in vitro. Ultrastructural features of a new model. J Am Acad Dermatol (1987) 0.88
Isolation of human sebaceous glands and cultivation of sebaceous gland-derived cells as an in vitro model. J Invest Dermatol (1989) 0.87
Properties and differential regulation of two fatty acid binding proteins in the rat kidney. J Biol Chem (1988) 0.87
Corticosteroids induce proliferation but do not influence TNF- or IL-1 beta-induced ICAM-1 expression of human dermal microvascular endothelial cells in vitro. Arch Dermatol Res (1993) 0.87
Cultivation of human dermal microvascular endothelial cells in vitro: immunocytochemical and ultrastructural characterization and effect of treatment with three synthetic retinoids. Arch Dermatol Res (1991) 0.86
Secreted phosphoprotein markers for neoplastic transformation of human epithelial and fibroblastic cells. Cancer Res (1985) 0.86
Proteins that bind the Src homology 3 domain of CrkI have distinct roles in Crk transformation. Oncogene (2010) 0.84
Osteopontin at the tumor/host interface. Functional regulation by thrombin-cleavage and consequences for cell adhesion. Ann N Y Acad Sci (1995) 0.83
Cytokine-stimulated human dermal microvascular endothelial cells produce interleukin 6--inhibition by hydrocortisone, dexamethasone, and calcitriol. J Invest Dermatol (1992) 0.82
The complex of FK506-binding protein 12 and FK506 inhibits calcineurin phosphatase activity and IgE activation-induced cytokine transcripts, but not exocytosis, in mouse mast cells. J Immunol (1995) 0.82
[Linear hyperpigmentation caused by bleomycin]. Hautarzt (1992) 0.81
[Stability of cignolin (dithranol) in ointments containing tar with and without the addition of salicylic acid. Oxidation to danthron and dithranol dimer]. Hautarzt (1987) 0.81
T24 human bladder carcinoma cells with activated Ha-ras protooncogene: nontumorigenic cells susceptible to malignant transformation with carcinogen. Proc Natl Acad Sci U S A (1988) 0.81
Isolation and culture of microvascular endothelial cells. Methods Mol Med (1999) 0.80
Culture of human sebocytes and markers of sebocytic differentiation in vitro. Skin Pharmacol (1991) 0.80
A rapid fluorometric assay for the determination of keratinocyte proliferation in vitro. J Invest Dermatol (1989) 0.79
Antisense oligonucleotides inhibit vascular endothelial growth factor/vascular permeability factor expression in normal human epidermal keratinocytes. J Invest Dermatol (1997) 0.78
Degeneration of granule cells following chronic phenytoin administration: an electron microscopic investigation of the mouse cerebellum. Exp Neurol (1986) 0.77
[Large cell anaplastic Ki-1 positive lymphoma of the skin. 5 personal cases and review of the literature]. Hautarzt (1995) 0.77
Enhanced interaction of patients' lymphocytes with human dermal microvascular endothelial cell cultures in active Adamantiades-Behçet disease. Arch Dermatol (1996) 0.76
Independent regulation of adipose tissue-specificity and obesity response of the adipsin promoter in transgenic mice. J Biol Chem (1994) 0.76
Effects of azelaic acid on sebaceous gland, sebum excretion rate and keratinization pattern in human skin. An in vivo and in vitro study. Acta Derm Venereol Suppl (Stockh) (1989) 0.75
Retinoids and keratinocyte differentiation in vitro. Dermatologica (1987) 0.75
[Bacillary epithelioid angiomatosis in advanced HIV infection]. Hautarzt (1993) 0.75
[Preliminary findings on lectin binding in human follicular epithelium]. Z Hautkr (1990) 0.75
[Dicarboxylic acids inhibit the growth of keratinocytes in vitro]. Hautarzt (1986) 0.75
Growth characteristics and differentiation of basal cell carcinoma in vitro--immunohistochemical, gel electrophoretic, and ultrastructural analysis. J Invest Dermatol (1992) 0.75
[Pre-myopathic versus amyopathic dermatomyositis. 2 personal cases and review of the literature]. Hautarzt (1995) 0.75
Blood flow and metabolism in heterotopic cerebellar grafts during hypoglycemia. Acta Neuropathol (1988) 0.75
[Multicentric reticulohistiocytosis and myelodysplastic syndrome]. Hautarzt (1994) 0.75
Vellus hair follicle-derived keratinocyte culture: a new experimental model in human hair research. Skin Pharmacol (1994) 0.75
[Granulocyte colony stimulating factor (G-CSF) in treatment of patients with HIV-associated mucocutaneous Kaposi sarcoma. Successful use in virus and drug-induced leukopenia]. Hautarzt (1992) 0.75
Nucleolysis and diskography--an experimental study on interaction of chymopapain and contrast medium. Neuroradiology (1987) 0.75